Introduction {#s1}
============

Methamphetamine abuse, a major illicit drug problem ([@CIT0018]), is resistant to treatment. Psychosocial interventions, the core of contemporary treatment for stimulant-use disorders, relieve only a portion of sufferers ([@CIT0025]), but effective medications are unknown ([@CIT0043]). Most stimulant abusers enter treatment in the first 7 to 10 days of abstinence ([@CIT0014]), the acute phase of withdrawal ([@CIT0057]). In this acute phase, risk of noncompliance is high, crucially affecting engagement, retention, and treatment outcome ([@CIT0006]). For this reason, neuroimaging at our center ([@CIT0025]; [@CIT0005]; [@CIT0004]; [@CIT0051]; [@CIT0027]) and a few others ([@CIT0024] [@CIT0023]; [@CIT0015]) has focused on characterizing the brain in acute abstinence from methamphetamine to inform development of novel and improved avenues to remediation.

Proton magnetic resonance spectroscopy (MRS) is a noninvasive neuroimaging technique used in several studies, mainly of longer term abstinence from methamphetamine ([@CIT0016]; [@CIT0029] [@CIT0030]; [@CIT0042]; [@CIT0008]; [@CIT0037] [@CIT0038] [@CIT0039]; [@CIT0047]; [@CIT0049]; [@CIT0036]; [@CIT0009]; [@CIT0020]). MRS assays the concentrations of several key metabolites potentially affected by methamphetamine in the living human brain. [@CIT0015] partly characterized the metabolic state of the brain in early abstinence with MRS. They identified one putative feature of this state: below-normal levels of glutamate+glutamine (Glx). Glx is a signal forming part of the MR spectrum; the magnitude of this signal is proportional to the sum of the concentrations of the amino acid and excitatory neurotransmitter glutamate (Glu) and the closely related neutral amino acid glutamine (Gln). The structural affinity of Glu and Gln renders them challenging to distinguish with MRS; hence, they are often assayed as a combined entity, Glx. [@CIT0015] showed evidence for a depletion of these glutamatergic compounds in methamphetamine abuse. In the first 2 months of abstinence, they measured below-normal Glx in anterior middle cingulate. (The anterior middle cingulate is located just caudal and dorsal to the portion of the cingulate that caps the genu of the corpus callosum; [@CIT0031]). The authors deduced that low Glx corresponded to a downregulation of brain Glu-Gln systems induced in early abstinence, perhaps a rebound from elevated levels of these compounds prevailing in times of active abuse. Their interpretation was supported by a positive correlation between Glx and length of abstinence (ie, recovery of Glx) across their sample as well as by within-subject increases in Glx observed longitudinally during the course of abstinence. Multiple neurochemical interpretations of these findings were offered, including methamphetamine-associated disturbances in the Krebs cycle and/or the neuronal-astrocytic Glu-Gln cycle as well as cell damage and microglial activation.

Here, we further explore low Glx in early abstinence from methamphetamine. We sought to determine if the putative Glx deficit manifests in cortical regions beyond anterior middle cingulate. Thereby, we targeted regions implicated in methamphetamine abuse in prior work using other neuroimaging modalities. One such region was the medial parietal cortex. Using ^18^FDG-PET, [@CIT0053] established that methamphetamine-abusing subjects abstinent for 2 weeks to 2 years had above-normal absolute cerebral metabolic rate of glucose (CMRglc) in medial parietal cortex. We later showed that research participants who had chronically used methamphetamine and then maintained abstinence for 4 to 7 days showed elevated relative CMRglc in medial parietal cortex and adjacent posterior middle cingulate cortex ([@CIT0025]) and that CMRglc increased during the first month of abstinence from methamphetamine, especially in medial parietal cortex ([@CIT0004]). Given the metabolic coupling between Glu and CMRglc in brain ([@CIT0044]), such effects might also influence the MRS Glx peak. We divided the medial parietal target into posterior cingulate cortex and the immediately dorsal precuneus, a division motivated by our earlier structural MRI work that had revealed below-normal gray-matter volume in methamphetamine-abusing subjects in posterior cingulate, but not precuneus ([@CIT0005]). A second target region was inferior frontal cortex, selected because the right inferior frontal cortex has been assigned a special role in behavioral response inhibition ([@CIT0001]), which is impaired in subjects during early abstinence from chronic methamphetamine abuse ([@CIT0026]). In addition, we have observed a deficit in gray matter of right inferior frontal gyrus in these subjects ([@CIT0005]; [@CIT0048]). This deficit partly recovers in the course of longer abstinence ([@CIT0027]). We hypothesized that Glx would be below normal in dorsal posterior cingulate, precuneus, and inferior frontal cortex and that Glx in these regions would be negatively correlated with duration of methamphetamine abuse. If low cortical Glx is a feature of early abstinence from methamphetamine, then it might contribute to behavioral symptoms during early abstinence, such as depressive symptoms ([@CIT0025]; [@CIT0057]). We hypothesized that Glx in our target regions would be negatively correlated with the severity of depressive symptoms, measured by the Beck Depression Inventory (BDI; [@CIT0003]). We tested these hypotheses in an inpatient sample of early (4--7 days) abstinent methamphetamine-abusing subjects and age-and sex-matched healthy control subjects.

Methods {#s2}
=======

Subjects {#s3}
--------

Forty-four methamphetamine-abusing and 24 healthy control subjects ([Table 1](#T1){ref-type="table"}), recruited via local print and radio ads, were enrolled into 2 groups: methamphetamine and control. Inclusion criteria for both groups were: (1) moderate or above intelligence (score \>85 on the Shipley Institute of Living Scale; [@CIT0055]), (2) right-handedness (score \>20 on a modified Edinburgh Handedness Test), (3) taking no prescription medications or herbal products (eg, *Ginkgo biloba*) expected to affect brain function, and (4) no current Axis I psychiatric disorders, including substance dependence disorders other than nicotine dependence (or methamphetamine dependence for the methamphetamine group). Absence of psychiatric disorders was established by in-person screening with the Structured Clinical Interview for DSM-IV. All participants with a history of notable head trauma, neurological disease, cardiovascular or pulmonary disease, or other significant major medical conditions, such as seropositivity for HIV, were excluded. Because of the high prevalence of tobacco smoking among methamphetamine-abusing subjects, an effort was made to match the 2 groups for cigarette smoking. Recent smoking was verified by carbon monoxide levels in expired air ≥10 ppm (Micro smokerlyzer; Bedfont Scientific Ltd, Kent, UK) and the presence of urinary cotinine (≥200ng/mL by Accutest NicAlert strips; JANT Pharmacal Corporation, Encino, CA). Mean nicotine dependence (Fagerström score), cumulative lifetime exposure (pack-years) to tobacco, marijuana consumption (days in past 30 days), and ethanol consumption did not differ significantly between groups ([Table 1](#T1){ref-type="table"}). After receiving a detailed explanation of the study, all subjects gave written informed consent to participate.

###### 

Clinical Characteristics of Study Subjects.

  ----------------------------------------------------------------
                          Methamphetamine\   Control\   *P*
                          (n = 44)           (n = 24)   
  ----------------------- ------------------ ---------- ----------
  Sex                                                   0.833

   Female                 19                 11         \--

   Male                   25                 13         \--

  Age, yr                 33.0±9.4           33.0±7.4   0.989

  Depression, BDI Score   13.3±11.5          1.8±2.5    \<0.0005

  Years Meth Abuse        11.1±7.8           0          \--

  g/week Meth             1.9±1.4            0          \--

  Pack-Years Tobacco      10.9±11.6          9.3±8.0    0.508

  Fagerström Score        3.0±2.2            3.5±2.3    0.474

  day/month Marijuana     0.7±1.2            0.4±1.3    0.439

  drink/week Ethanol      1.6±2.3            2.6±2.5    0.113
  ----------------------------------------------------------------

Shown are subject numbers or group mean±standard deviation. *P* values

are for χ^2^ (sex) or two-way independent t-tests (all other variables).

Participants in the methamphetamine group resided in the UCLA General Clinical Research Center inpatient unit during their participation. They all denied a desire to seek treatment yet were willing to remain abstinent from methamphetamine for the course of the study and were paid for their participation, including remaining abstinent from methamphetamine. These participants had to satisfy DSM-IV criteria (established by Structured Clinical Interview) for methamphetamine dependence and demonstrate use of methamphetamine within 3 days of enrollment, as verified by a positive urine toxicology screen. Thereafter, subjects were under regular supervision of medical staff and underwent twice-weekly random urine screens to confirm abstinence from illicit drugs of abuse. Methamphetamine abuse variables, including duration of abuse in years and current intensity of methamphetamine abuse in grams per week ([Table 1](#T1){ref-type="table"}), were solicited by structured interview at the time of enrollment. Participants in the control group were matched to the methamphetamine group for age and sex ([Table 1](#T1){ref-type="table"}). MR scans were performed within 4 to 7 days of admission, and participants in both groups evidenced negative urine screens on the day of the scan. In the same timeframe, the BDI was administered to assess depressive symptoms. In early abstinence, methamphetamine-dependent subjects exhibit depressive symptoms and symptoms of psychosis, both of which largely resolve within a week of abstinence, although drug craving does not significantly decrease from the time of initiating abstinence until the second week ([@CIT0057]). The study was approved by the UCLA Office for Protection of Human Subjects.

Magnetic Resonance Acquisition {#s4}
------------------------------

Proton MRS imaging (MRSI), the multivoxel version of MRS, and prescriptive structural MRI were acquired together in a single session. Acquisitions were performed on a 1.5-T magnetic resonance scanner (Siemens Sonata) using a standard quadrature head coil. In addition to MRSI, scanning sequences included a localizer scout and a high-resolution T1-weighted whole-brain MRI. Water-suppressed PRESS MRSI (repetition time =1500ms, echo time =30ms, number of excitations =8, in-plane resolution: 11x11mm^2^, slab thickness: 12mm for medial parietal or 9mm for inferior frontal with nominal voxel size 1.4 or 1.1 cc, respectively) was acquired from three 2-dimensional slabs ([Figure 1](#F1){ref-type="fig"}). The first slab was oriented sagitally and straddled the longitudinal midline sampling posterior cingulate cortex ventrally and precuneus dorsally. The posterior cingulate was a mixture of dorsal and ventral posterior cingulate cortex, as defined by Vogt ([@CIT0031]). The second and third slabs were sagittal-oblique (roughly parallel to the ipsilateral temple) in orientation and sampled the left, respectively right, peri-Sylvian region, including inferior frontal gyrus and other nearby cortex. Each of the 3 MRSI slabs was followed by an identical acquisition (only 1 number of excitation) with water-suppression turned off.

![Sagittal (A), axial-oblique (B), and coronal-oblique (C) magnetic resonance imaging (MRI) of the brain showing "medial parietal" magnetic resonance spectroscopy imaging (MRSI) slab. The white square in a is A 12-mm--thick PRESS-select volume, consisting of 4x4 MRSI voxels, each 11x11mm^2^ in-plane; the blue square within the white square is one such voxel. The rear edge of the slab was aligned parallel to the parieto-occipital sulcus; the lower edge was parallel or tangent to the dorsal margin of the isthmus or splenium of the corpus callosum. The most ventral voxel row samples posterior cingulate (blue square) and dorsal rows sample mainly precuneus. Sagittal-oblique (D), coronal (E), and axial-oblique (F) MRI depicting positioning of 9-mm--thick MRSI slabs in peri-Sylvian region. The PRESS volume was aligned parallel to the temple, set approximately 2cm deep into the brain, sized to anatomy, and rotated counter-clockwise parallel to the Sylvian fissure to sample inferior frontal cortex (blue square in D-F).](ijnppy_pyu059_f0001){#F1}

Magnetic Resonance Postprocessing {#s5}
---------------------------------

The whole-brain T1-weighted volume of each subject was transformed into ICBM152 stereotaxic space, skull-stripped, and segregated into gray-matter, white-matter, and cerebrospinal fluid (CSF) subvolumes using the Statistical Parametric Mapping 5 software suite. Each whole-brain tissue subvolume was converted into a binary mask and transformed back into native space.

MRSI spectra were automatically fit with LCModel, yielding fitted peaks with absolute metabolite levels referenced to the unsuppressed water resonance and expressed in IU. Fitted peaks included Glx as well as other metabolites, which were not evaluated in this study. Numerous weaker resonances, in particular lipids and macromolecules, were included in the fit. The MRSI Voxel Picker (MVP) software suite ([@CIT0041]) was used for MRI/MRSI co-processing. The T1-weighted volume and the gray-matter, white-matter, and CSF binary masks were imported into MVP as well as the MRSI raw data file and LCModel output. For each subject's MRSI slab, MVP reconstructed the T1-weighted volume and displayed it in a guided user interface in register with the corresponding MRSI PRESS volume in its plane of acquisition. MVP similarly reconstructed each mask and computed the volume percent gray matter, white matter, and CSF in each MRSI voxel. Then MVP corrected the LCModel-derived levels of each metabolite for voxel CSF content. Quality control of MRSI spectra was also automatically implemented by MVP supplemented by operator inspection. Only those spectra that exhibited linewidth ≤0.1 ppm and signal-to-noise ratio ≥5 were retained. Furthermore, within each voxel, only those Glx values were retained that were considered reliable by LCModel (standard deviation of metabolite signal \<20%). Voxels were selected by a diagnosis-blind operator on the MVP guided user interface in left and right hemispheres for inferior frontal cortex, defined using protocols developed at our center ([@CIT0005]). Posterior cingulate and precuneal voxels comprised a roughly equal mixture of left and right hemispheres. Within each structure, MVP averaged the metabolite levels for all voxels that contained ≥60 volume percent gray matter and that satisfied the above quality-control criteria.

Statistics {#s6}
----------

Not all the subjects of [Table 1](#T1){ref-type="table"} had usable Glx data for all 4 brain regions. In some cases, data were missing, because the scanning session was aborted early due to technical difficulties or subject compliance. This most affected the medial parietal slab, which was run late in the session. Other data were rejected, because they failed to meet the above-listed quality-control criteria. Consequently, the 2 subject groups were compared for sex, age, and smoking not just for the overall sample ([Table 1](#T1){ref-type="table"}) but also for each of the 4 regions individually using only the subjects who had usable Glx data for that region. The numbers of subjects with usable data for each region are given in [Table 2](#T2){ref-type="table"}. The χ^2^ test was used to compare sex and independent *t* test was used to compare all other between-group variables. To assess possible confounds due to partial-volume effects, volume percent gray matter, white matter, and CSF were also compared between groups using independent *t* test in each individual region. Any of the aforementioned variables significantly differing between the groups was applied as a covariant in subsequent analyses in the relevant brain regions. Finally, mean BDI score was compared between groups for the overall sample using independent *t* test ([Table 1](#T1){ref-type="table"}). Mean BDI score was expected to be much higher for the methamphetamine group than for the control group, as acute depression is an established clinical feature of methamphetamine withdrawal ([@CIT0025]; [@CIT0057]). Therefore, BDI score was not used as a covariate in subsequent analyses.

###### 

Subject Numbers, MRSI Voxel Tissue Composition and Glx Levels in Target Cortices.

                 Posterior Cingulate            Precuneus                                         
  -------------- ------------------------------ ------------------------------- ----------------- ----------
  subjects       39                             17                              30                15
  gray matter    77.1±2.9                       77.5±3.6                        73.9±3.3          73.2±2.9
  white matter   8.2±4.0                        8.2±5.7                         7.3±3.5           9.1±3.8
  CSF            14.7±4.1                       14.2±4.1                        18.7±4.0          17.5±4.6
  Glx            12.6±1.5\*                     13.7±1.4                        12.2±1.7\*        13.2±1.3
                 Left Inferior Frontal Cortex   Right Inferior Frontal Cortex                     
                 Methamphetamine                Control                         Methamphetamine   Control
  subjects       41                             23                              38                20
  gray matter    73.5±4.9                       72.8±5.4                        73.4±4.3          73.8±5.3
  white matter   10.7±5.9                       12.1±5.4                        10.7±5.2          10.7±6.0
  CSF            15.8±5.4                       15.0±4.9                        15.8±5.0          15.3±7.5
  Glx            12.4±2.2                       12.7±2.3                        12.7±2.5\*        14.6±2.6

Listed are numbers of subjects with usable Glx data in each target cortex.

Gray matter-, white matter-, CSF-content expressed as percent of total MRSI voxel volume.

Glx levels corrected for voxel CSF-content.

Tissue composition and Glx values are group means ± standard deviation.

Significant between-group comparisons (\**P*\<0.05, *post-hoc* t-test following R-ANOVA)

An omnibus approach to multiple comparisons was taken for between-group tests of mean Glx. A repeated-measures analysis of variance was performed with Glx as measure, "region" as within-subjects factor (4 levels for the 4 cortical regions), and "diagnosis" as between-subjects factor (2 levels: methamphetamine and control). This was followed by posthoc *t* tests comparing mean Glx between the 2 groups in each region. For any region showing a significant between-group difference in Glx, we then ran, within the methamphetamine group, a Spearman correlation of Glx vs duration of methamphetamine abuse in years partialling age. Finally, we ran a Pearson correlation in the region within the methamphetamine group of Glx vs BDI score. The criterion for statistical significance for all tests was *P*\<.05.

Results {#s7}
=======

Clinical Characteristics {#s8}
------------------------

In the overall sample ([Table 1](#T1){ref-type="table"}), there were no significant between-group differences in sex or mean age, pack-years of cigarettes, or Fagerström score. When retested for subjects having usable Glx data in each of the 4 cortical regions, there were again no significant between-group differences. Therefore, it was not necessary to use any of these variables as a covariate in subsequent analyses. As expected, mean depressive symptoms, as assessed by BDI score, were higher for the methamphetamine (13.3±11.5) than for the control (1.8±2.5) group (t~50.0~=6.3, *P*\<.0005).

MRSI Voxel Tissue Content {#s9}
-------------------------

There were no significant between-group differences in volume percent gray matter, white matter, or CSF in any region ([Table 2](#T2){ref-type="table"}). When the 2 subject groups were divided into male and female subgroups and then compared by diagnosis, there were also no significant differences in volume percent gray matter, white matter, or CSF in any region. Note that these volume percentages are amounts of gray matter, white matter, and CSF in the MRSI sampling volume, which typically occupy only a fraction of the target brain region. Thus, these measures are unsuitable to quantify atrophy or other volumetric effects on the region as a whole. Their purpose, rather, is to ensure that apparent between-group differences in metabolite levels are not confounded by between-group differences in MRSI voxel tissue composition.

Regional Glx Levels and Correlations with Duration of Methamphetamine Abuse and BDI {#s10}
-----------------------------------------------------------------------------------

Repeated-measures analysis of variance of Glx levels across the 4 cortical regions yielded a significant main effect of diagnosis (F~1,36~=4.8, *P*=.035) ([Table 2](#T2){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}). Posthoc examination of the 4 target regions revealed significantly lower mean Glx for the methamphetamine than the control group in posterior cingulate (39 methamphetamine subjects/17 controls with usable data, 8.1% deficit, t~32.5~=2.7, *P*=.011), precuneus (30/15, 7.9%, t~35.0~=2.2, *P*=.031), and right inferior frontal cortex (38/20, 12.8%, t~37.7~=2.6, *P*=.013), but not in left inferior frontal cortex ([Figure 2](#F2){ref-type="fig"}). When the 2 subject groups were divided into male and female subgroups, similar regional deficits in Glx were observed for the methamphetamine relative to the control group in both sexes in posterior cingulate (male 8.0% deficit, female 7.5%), precuneus (male 6.6%, female 9.7%), and right inferior frontal cortex (male 15.1%, female 9.2%), but not in left inferior frontal cortex (male 3.1% surplus, female 7.2% deficit). For males and females together, there was a notable (15.4%) right \> left asymmetry in inferior frontal cortex in Glx within controls (paired t~20~=3.5, *P*=.014) that was not seen in the methamphetamine group (t~37~=0.8, *P*=.444).

![(Left) Levels of Glx (glutamate \[Glu\]+glutamine \[Gln\]) measured by magnetic resonance spectroscopy imaging (MRSI) in midline (left+right) posterior cingulate cortex (upper panel) and right inferior frontal cortex (lower panel) in early (4--7 days) abstinent methamphetamine abusers (circles) and age-and sex-matched healthy controls (triangles). Horizontal bars denote group means. Note lower mean Glx in the methamphetamine group in both cortices, 8.1% in midline posterior cingulate (t~32.5~=2.7, *P*=.011), and 12.8% in right inferior frontal cortex (t~37.7~=2.6, *P*=.013), suggesting local downregulation of brain glutamatergic systems in early abstinence. A similar Glx deficit (not shown) was observed in precuneus (7.9%, t~35.0~=2.2, *P*=.031). (Right, upper) Within the methamphetamine sample, Glx in posterior cingulate decreases with increasing years of abuse (*df*=36, *r*=-0.42, *P*=.008, partial age). (Lower) In right inferior frontal cortex, Glx in the methamphetamine sample decreases with increasing depressive symptoms on the Beck Depression Inventory (BDI; *df*=38, *r*=-0.45, *P*=.005). Metabolite levels in IU corrected for voxel CSF content. \**P*\<.05, \*\**P*\<.01.](ijnppy_pyu059_f0002){#F2}

Within the methamphetamine group, Glx in posterior cingulate decreased with increasing years of abuse (*df*=36, *r*=-0.42, *P*=.008, partial age) ([Figure 2](#F2){ref-type="fig"}). This relationship was not significant in the other 3 regions. In right inferior frontal cortex, Glx in the methamphetamine group decreased with increasing depressive symptoms on the BDI (*df*=38, *r*=-0.45, *P*=.005) ([Figure 2](#F2){ref-type="fig"}). This relationship was not significant in the other 3 regions.

Discussion {#s11}
==========

Cortical Glx Deficits {#s12}
---------------------

This is 1 of only 2 proton MRSI studies of the brain in subjects who had chronically abused methamphetamine; the other is by [@CIT0020]. As noted, several studies used single-voxel proton MRS to investigate effects of methamphetamine abuse on neurometabolites ([@CIT0016]; [@CIT0029] [@CIT0030]; [@CIT0042]; [@CIT0008]; [@CIT0037] [@CIT0038] [@CIT0039]; [@CIT0047]; [@CIT0049]; [@CIT0036]; [@CIT0009]; [@CIT0020]). Most studies predominantly examined patients who had been long-term abstinent from methamphetamine. Similar to [@CIT0015] and [@CIT0054], the former finding diminished Glx in anterior cingulate of methamphetamine-abusing humans and the latter finding it in methamphetamine-exposed monkeys, we focused on the acute phase of abstinence. We used short echo-time MRSI to assay Glx from multiple cortices at high spatial resolution. Poorly accessible inferior frontal cortex was sampled with the help of an innovative sagittal-oblique slab prescription. Voxel tissue-composition was determined and used to mitigate partial-volume effects, yielding high voxel tissue purity ([Table 2](#T2){ref-type="table"}).

This study yielded 3 major findings. The first was modestly (7--13%) lower levels of Glx in acute abstinence from methamphetamine abuse (vs in the control group) in 3 cerebral cortical regions: posterior cingulate, precuneus, and right inferior frontal cortex. Second, in one of these regions, posterior cingulate, Glx decreased with increasing years of methamphetamine abuse. Third, in another region, right inferior frontal cortex, Glx decreased with increasing depressive symptoms. Taken together, these findings support the notion advanced by [@CIT0015] of a downregulation of brain glutamatergic systems in the early days of withdrawal from methamphetamine and suggest that this phenomenon is not limited to the anterior middle cingulate.

The finding of a deficit in Glx in posterior cingulate, precuneus, and right inferior frontal cortex of methamphetamine abusers ([Table 2](#T2){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}) extends prior work with imaging modalities other than MRSI. In posterior cingulate and precuneus, ^18^FDG-PET previously demonstrated elevated glucose metabolism in methamphetamine-abusing subjects following up to14 days ([@CIT0025]) or 14 days to 2 years ([@CIT0053]; [@CIT0004]) abstinence from drug. In combination with these findings, the present results reinforce the view that methamphetamine abuse is associated with dysfunction in brain areas, such as medial parietal cortex, with sparse dopaminergic innervation ([@CIT0012]). Glx in the methamphetamine group also was below control levels in the right inferior frontal cortex. Notably, this deficit reflected the absence of a right\>left excess of Glx seen in the controls ([Table 2](#T2){ref-type="table"}). The right inferior frontal gyrus has been linked to response inhibition ([@CIT0001]; but see [@CIT0046]), a cognitive function thought to be impaired in methamphetamine abuse ([@CIT0026]; for review, see [@CIT0002]), and to methamphetamine craving as well as emotion regulation ([@CIT0048]). Although we are unaware of previous MRS studies sampling inferior frontal cortex in subjects who had abused methamphetamine, in our previous published work, we have observed deficits in gray matter in this region in such subjects ([@CIT0005]; [@CIT0048]). We did not observe Glx effects in left inferior frontal cortex. The present findings add to evidence that inferior frontal cortex is particularly affected by methamphetamine abuse and/or withdrawal and support our previous observations of a lateralization of methamphetamine-associated pathology ([@CIT0005]; [@CIT0027]), perhaps related to the imputed lateralization of function (motor language, response inhibition) in this region.

Our second major finding was that, within the methamphetamine group, Glx in posterior cingulate decreased with increasing years of abuse. In anterior middle cingulate, [@CIT0015] found no significant relationship between Glx and methamphetamine abuse, operationalized as the logarithm of cumulative lifetime exposure. This negative result fortified their argument that low Glx levels are a more direct effect of withdrawal than of abuse per se. Our result does not disagree with this interpretation, because if a drop in cortical Glx is induced by withdrawal, a greater drop might be seen following more severe prewithdrawal abuse. It also may be noteworthy that although [@CIT0015] assessed Glx in the anterior middle cingulate cortex, the finding here was related to an observation in posterior cingulate.

The observation that Glx in the inferior frontal cortex of the right hemisphere was negatively associated with BDI score is of interest in the context of recent research that has been uncovering links between depression and central glutamatergic systems, including rapid responses to treatments for otherwise refractory depression ([@CIT0040]; [@CIT0056]). These treatments include most notably NMDA receptor antagonists such as ketamine. Within the narrower context of methamphetamine use disorders, severity of depressive symptoms positively covaried with relative CMRglc in subgenual and pregenual anterior cingulate cortices during early abstinence from the drug ([@CIT0025]), whereas BDI score covaried with relative CMRglc in right inferior frontal cortex within a healthy control group. Cortical volume in right inferior frontal gyrus and in multiple right-hemisphere, cingulate subregions also was below control values in a partially overlapping sample of methamphetamine users ([@CIT0005]).

Since the discovery of the "catastrophic reaction" following left-hemisphere middle cerebral artery infarcts ([@CIT0017]), the inferior frontal cortex has been linked with the lateralization of emotion in as yet unclear ways, although the pars orbicularis of this region has been implicated in inhibitory control in multiple modalities, including emotion regulation ([@CIT0048]). The right hemisphere is thought to dominate over the left in the expression of all or of only negative emotions ([@CIT0019]), with right-hemisphere overactivation possibly generating negative emotions ([@CIT0011]), or depression impairing right-hemisphere function ([@CIT0052]). The present Glx result adds to evidence associating depression with inferior frontal lateralization. Moreover, it points to a linkage between depression in acute withdrawal from methamphetamine and Glu metabolism, although depressive symptoms may predate and possibly predispose an individual to methamphetamine use. As conventional serotonergic agents perform poorly in treating the depression of methamphetamine withdrawal, the poor response to serotonergic treatment correlating with high craving for methamphetamine and relapse ([@CIT0058]), glutamatergic alternatives might be useful for treating this condition. We are unaware of published or ongoing clinical trials or case studies involving glutamatergic drugs for methamphetamine use disorders, although there is some relevant preclinical work ([@CIT0007]; [@CIT0021]).

[@CIT0015] reported reduced Glx in anterior middle cingulate of methamphetamine users, including measurements during the early abstinence phase examined in the present study. Since the anterior middle cingulate was not sampled in the present study, it is not known whether the methamphetamine sample exhibited below-normal Glx in anterior middle cingulate along with the other brain regions, although it is possible. In any case, the mechanisms proposed by [@CIT0015] to explain reduced Glx in anterior middle cingulate of patients with methamphetamine use disorder also likely apply in the cortical regions investigated here. Briefly, the mechanisms include loss of glutamatergic neurons, decreased Glu synthesis by the Krebs cycle (inhibited mitochondrial function), reduced astrocyte uptake and recycling of Glu as Gln, and increased demand for Glu and Gln as amino acids to repair cell structures damaged by methamphetamine. Thus, there may be multiple, possibly overlapping, pathophysiological pathways to low cortical Glx following methamphetamine abuse. Regarding the medial parietal regions, posterior cingulate, and precuneus particularly, as discussed by [@CIT0053], animal studies indicate that the parietal cortex is especially sensitive to methamphetamine toxicity ([@CIT0033]), including damage to pyramidal glutamatergic cells ([@CIT0010]; [@CIT0035]). Methamphetamine also upregulates Glu receptors in parietal cortex ([@CIT0013]), increasing their sensitivity to glutamatergic excitotoxicity. These factors may contribute to regional drop in Glx. A further factor is methamphetamine toxicity mediated by σ-receptors ([@CIT0022]), which have high density in posterior cingulate ([@CIT0045]).

This study has limitations. MRSI was acquired at 1.5 T, making segregation of Glx into Glu and Gln more difficult. Although we believe that presentation of MRS Glu results is defensible even at 1.5 T, we opted for Glx as a metric of regional glutamatergic metabolism in this report, since the motivating results of [@CIT0015] and [@CIT0054] were expressed as Glx. Further work at high field strength is nonetheless encouraged. Due to incomplete acquisition and rejection of data not meeting spectral quality or tissue-content standards, Glx values were missing for a number of subjects in some brain regions. Actual subject numbers analyzed for each region are indicated in [Table 2](#T2){ref-type="table"}. Potential confounds arising from this matter were addressed by confirming that the 2 subject groups were still balanced for sex, age, smoking, and MRSI voxel tissue-content in each region individually after accounting for these missing values. Whereas single-voxel MRS typically offers more rapid acquisition with higher signal-to-noise ratio, MRSI has the advantage of smaller voxel size and hence lower chance of confounding of results due to partial-volume effects. Our study also has certain uncommon strengths, one of these being matching of subject groups for tobacco smoking. Such matching may be critical for any study of glutamatergic compounds in methamphetamine abuse. Our work ([@CIT0032]) suggests that cigarette smoking, extremely prevalent among methamphetamine abusers, is associated with low Glx in at least one brain region, the thalamus. Overall, the present investigation supports the notion of downregulation of glutamatergic metabolism in multiple cerebral cortices in very early abstinence from methamphetamine; low Glx may be associated with the depressive component of the methamphetamine withdrawal syndrome, which is presumably an important driver of relapse.

Statement of Interest
=====================

None of the authors have a financial relationship with any organization that sponsored this research, and all authors declare that they have no conflicts of interest.

This work was supported by the National Institute on Drug Abuse (P20DA022539 to E.D.L., R01DA020726 to E.D.L., R03DA20512 to J.O.N., and R21DA023192 to J.O.N.), the National Center for Research Resources (MOIRR00865 from the UCLA General Clinical Research Center), and endowments from the Thomas P. and Katherine K. Pike Chair in Addiction Studies and the Marjorie M. Greene Trust to E.D.L.
